Prevalence and Infectivity of Asymptomatic COVID-19 Illness
Author(s): Rudra Rajesh Nair, Abhishek Ingole* and Ashok Mehendale
Abstract
The Severe Acute Respiratory Syndrome Corona Virus 2 is a novel coronavirus (SARS-CoV-2), triggered a coronavirus disease outbreak in December 2019. Acute respiratory distress syndrome, acute renal failure, acute respiratory injury, septic shock, and severe pneumonia are all manifestations of acute respiratory distress syndrome that have all been recorded in 33% of patients who have received COVID-19. COVID-19 has no specific medication or vaccine that has been approved, and several clinical trials are now studying potential COVID-19 treatments. Some carcinoma patients' immunosuppression (either induced by the disease or treatment) makes them more susceptible to infection. Presently, extensive studies and efforts are done to understand the how the infection occurs and how to treat covid, but risk factors, the prognosis and outcomes after treatment are yet to be understood and interpreted. Clinical focus is immense. Supportive interventions like supply of oxygen, fluid intake, and fever and pain control, as well as medications if a pre-existing bacterial is present, have been recommended so far. Remdesivir, immune globulins, arbidol hydrochloride integrated with interferon atomization, and ASC09F are all now being tested in clinical studies as potential COVID-19 therapies. As an effort made to curb covid by respective authorities, complications may arise or progression to severity can occur in such immune compromised patients. The severity varies from one patient to another covid infected cancer patient. Based on the latest literature and researches, risk factors, radiological and biochemical characteristics, the impact on diagnosis and treatment and treatment outcomes have been discussed. The challenging scenario of taking care of covid infected cancer patients has been discussed.